AR025457A1 - Mesoprogestinas (moduladores de receptores de progesterona) para el tratamiento y la prevencion de trastornos ginecologicos benignos hormona-dependientes - Google Patents
Mesoprogestinas (moduladores de receptores de progesterona) para el tratamiento y la prevencion de trastornos ginecologicos benignos hormona-dependientesInfo
- Publication number
- AR025457A1 AR025457A1 ARP000104538A ARP000104538A AR025457A1 AR 025457 A1 AR025457 A1 AR 025457A1 AR P000104538 A ARP000104538 A AR P000104538A AR P000104538 A ARP000104538 A AR P000104538A AR 025457 A1 AR025457 A1 AR 025457A1
- Authority
- AR
- Argentina
- Prior art keywords
- treatment
- prevention
- disorders
- gynecological disorders
- mesoprogestins
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Abstract
Uso de mesoprogestinas, una nueva clase de moduladores de receptor de progesterona (MRP), para el tratamiento y la prevencion de trastornos ginecologicosbenignos hormona-dependientes: a) para el tratamiento de trastornos ginecologicos tales como lae ndometriosis, los fibromas uterinos, las adherenciasperitoneales postoperatorias, la hemorragia disfuncional (metrorragia, menorragia) y la dismenorragia; b) para prevenir trastornos ginecologicos tales como lasadherencias peritonealespostoperatoria s, hemorragia uterina disfuncional (metrorragia, menorragia) y dismenorragia; y c) un método para tratar y prevenir lostrastornos antes mencionados en una hembra, preferentemente una hembra humana, que necesite tratamiento oprevencion de uno o más d e los mencionados trastornoscon una cantidad efectiva de mesoprogestina. Las mesoprogestinas se definen como compuestos que disponen de actividad tanto agonística como antagonística en elreceptor de progesterona (RP) invivo. Estabilizan la funcion d e RP en un nivel intermedio entre agonístico y antagonístico. Las progestinas y lasantiprogestinas no permiten lograr los mismos estados funcionales. La dosis diaria de mesoprogestina es de 0,5 a 100 mg,preferentemente de 5,0 a 50 mg y máspreferente mente de 10 a 25 mg. J867, J912, J956 y J1042 son las mesoprogestinas preferidas de acuerdo con la presente.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38614199A | 1999-08-31 | 1999-08-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR025457A1 true AR025457A1 (es) | 2002-11-27 |
Family
ID=23524338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000104538A AR025457A1 (es) | 1999-08-31 | 2000-08-31 | Mesoprogestinas (moduladores de receptores de progesterona) para el tratamiento y la prevencion de trastornos ginecologicos benignos hormona-dependientes |
Country Status (34)
| Country | Link |
|---|---|
| EP (1) | EP1229906B1 (es) |
| JP (1) | JP2003535029A (es) |
| KR (3) | KR20080066095A (es) |
| AR (1) | AR025457A1 (es) |
| AT (1) | ATE375160T1 (es) |
| AU (1) | AU781840B2 (es) |
| BG (1) | BG65817B1 (es) |
| BR (1) | BR0014161A (es) |
| CA (1) | CA2382580C (es) |
| CO (1) | CO5200772A1 (es) |
| CZ (1) | CZ2002704A3 (es) |
| DE (1) | DE60036723T2 (es) |
| DK (1) | DK1229906T3 (es) |
| EA (1) | EA007854B1 (es) |
| EE (1) | EE05172B1 (es) |
| ES (1) | ES2295050T3 (es) |
| HR (1) | HRP20020267A2 (es) |
| HU (1) | HUP0202429A3 (es) |
| IL (1) | IL148416A0 (es) |
| LT (1) | LT5034B (es) |
| LV (1) | LV12941B (es) |
| ME (1) | MEP13808A (es) |
| MX (1) | MXPA02002191A (es) |
| NO (1) | NO20020999L (es) |
| NZ (1) | NZ517471A (es) |
| PE (1) | PE20010578A1 (es) |
| PL (1) | PL198790B1 (es) |
| PT (1) | PT1229906E (es) |
| RO (1) | RO122179B1 (es) |
| RS (1) | RS50283B (es) |
| SI (1) | SI20852B (es) |
| SK (1) | SK287192B6 (es) |
| UA (1) | UA78184C2 (es) |
| WO (1) | WO2001015679A2 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10236405A1 (de) | 2002-08-02 | 2004-02-19 | Schering Ag | Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie |
| ATE338763T1 (de) * | 2002-08-02 | 2006-09-15 | Schering Ag | Progesteronrezeptormodulatoren mit erhöhter antigonadotroper aktivität für die weibliche fertilitätskontrolle und hormonersatztherapie |
| US20040097591A1 (en) * | 2002-11-18 | 2004-05-20 | Kristof Chwalisz | Use of selective progesterone receptor modulators for the treatment of androgen deficiency |
| DE102007011105A1 (de) | 2007-03-02 | 2008-09-04 | Bayer Schering Pharma Aktiengesellschaft | Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose |
| KR20120064067A (ko) * | 2009-06-17 | 2012-06-18 | 고꾸리쯔다이가꾸호오진 구마모또 다이가꾸 | 월경곤란증의 예방 및/또는 치료약 |
| US8399432B2 (en) * | 2009-10-27 | 2013-03-19 | Lipogen Ltd. | Compositions and methods of treatment for alleviating premenstrual syndrome symptoms |
| US20220339176A1 (en) * | 2019-09-23 | 2022-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of Treatments to Prolong Gestation and Complications of Menstruation or Gestation |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3633244A1 (de) | 1986-09-26 | 1988-03-31 | Schering Ag | Antigestagene zur hemmung der uterinen prostaglandinsynthese |
| DE4332284C2 (de) | 1993-09-20 | 1997-05-28 | Jenapharm Gmbh | 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| DE4332283A1 (de) * | 1993-09-20 | 1995-04-13 | Jenapharm Gmbh | Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US5681817A (en) * | 1994-02-04 | 1997-10-28 | The Medical College Of Hampton Roads | Treatment of ovarian estrogen dependent conditions |
| US5576310A (en) * | 1994-09-20 | 1996-11-19 | Jenapharm Gmbh | 11-benzaldoxime-17β-methoxy-17α-methoxymethyl-estrasdiene derivatives, methods for their production and pharmaceuticals containing such compounds |
| US5696127A (en) * | 1994-12-22 | 1997-12-09 | Ligand Pharmaceuticals Incorporated | Steroid receptor modulator compounds and methods |
| DK0800519T3 (da) * | 1994-12-22 | 2004-03-01 | Ligand Pharm Inc | Steroidreceptormodulatorforbindelser og fremgangsmåder |
| ES2196063T3 (es) | 1995-02-02 | 2003-12-16 | Schering Ag | Utilizacion de agentes antagonistas competitivos de progesterona para la preparacion de medicamentos destinados al tratamiento de hemorragias uterinas disfuncionales. |
| DE19604231A1 (de) * | 1996-01-29 | 1997-07-31 | Schering Ag | Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen |
| HU230492B1 (hu) * | 1996-05-01 | 2016-08-29 | The Government Of The United States Of America | Új progesztációt gátló szerként használható 21-helyzetben szubsztituált progeszteron-származékok, ezeket tartalmazó gyógyszerkészítmények, alkalmazásuk |
| WO1998005679A2 (en) * | 1996-08-05 | 1998-02-12 | Duke University | Mixed agonists of the progesterone receptor and assays therefor |
| DE19809845A1 (de) * | 1998-03-03 | 1999-09-09 | Jenapharm Gmbh | S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen |
| AU2708700A (en) * | 1999-01-14 | 2000-08-01 | Bayer Corporation | Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents |
| CA2371273A1 (en) * | 1999-05-04 | 2000-11-09 | Andrew Fensome | Tetracyclic progesterone receptor modulator compounds and methods |
-
2000
- 2000-08-31 DK DK00957914T patent/DK1229906T3/da active
- 2000-08-31 EA EA200200282A patent/EA007854B1/ru not_active IP Right Cessation
- 2000-08-31 ES ES00957914T patent/ES2295050T3/es not_active Expired - Lifetime
- 2000-08-31 SI SI200020042A patent/SI20852B/sl not_active IP Right Cessation
- 2000-08-31 DE DE60036723T patent/DE60036723T2/de not_active Expired - Lifetime
- 2000-08-31 BR BR0014161-5A patent/BR0014161A/pt not_active Application Discontinuation
- 2000-08-31 UA UA2002032430A patent/UA78184C2/uk unknown
- 2000-08-31 IL IL14841600A patent/IL148416A0/xx unknown
- 2000-08-31 PE PE2000000893A patent/PE20010578A1/es not_active Application Discontinuation
- 2000-08-31 PL PL353930A patent/PL198790B1/pl not_active IP Right Cessation
- 2000-08-31 KR KR1020087016247A patent/KR20080066095A/ko not_active Application Discontinuation
- 2000-08-31 ME MEP-138/08A patent/MEP13808A/xx unknown
- 2000-08-31 KR KR1020077011455A patent/KR100864547B1/ko not_active IP Right Cessation
- 2000-08-31 SK SK299-2002A patent/SK287192B6/sk unknown
- 2000-08-31 AR ARP000104538A patent/AR025457A1/es unknown
- 2000-08-31 AT AT00957914T patent/ATE375160T1/de not_active IP Right Cessation
- 2000-08-31 CO CO00065515A patent/CO5200772A1/es not_active Application Discontinuation
- 2000-08-31 CA CA002382580A patent/CA2382580C/en not_active Expired - Lifetime
- 2000-08-31 AU AU69466/00A patent/AU781840B2/en not_active Ceased
- 2000-08-31 JP JP2001519893A patent/JP2003535029A/ja active Pending
- 2000-08-31 KR KR1020027002790A patent/KR100755109B1/ko not_active IP Right Cessation
- 2000-08-31 HU HU0202429A patent/HUP0202429A3/hu unknown
- 2000-08-31 WO PCT/US2000/023770 patent/WO2001015679A2/en active IP Right Grant
- 2000-08-31 NZ NZ517471A patent/NZ517471A/en unknown
- 2000-08-31 PT PT00957914T patent/PT1229906E/pt unknown
- 2000-08-31 CZ CZ2002704A patent/CZ2002704A3/cs unknown
- 2000-08-31 RO ROA200200229A patent/RO122179B1/ro unknown
- 2000-08-31 RS YUP-140/02A patent/RS50283B/sr unknown
- 2000-08-31 EE EEP200200104A patent/EE05172B1/xx not_active IP Right Cessation
- 2000-08-31 EP EP00957914A patent/EP1229906B1/en not_active Expired - Lifetime
-
2002
- 2002-02-26 BG BG106442A patent/BG65817B1/bg unknown
- 2002-02-28 MX MXPA02002191A patent/MXPA02002191A/es active IP Right Grant
- 2002-02-28 NO NO20020999A patent/NO20020999L/no not_active Application Discontinuation
- 2002-03-21 LT LT2002031A patent/LT5034B/lt not_active IP Right Cessation
- 2002-03-28 LV LVP-02-53A patent/LV12941B/lv unknown
- 2002-03-28 HR HR20020267A patent/HRP20020267A2/xx not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2281551T3 (es) | Metodo de prevencion o tratamiento de enfermedades ginecologicas benignas. | |
| Komisaruk et al. | Brain-mediated responses to vaginocervical stimulation in spinal cord-transected rats: role of the vagus nerves | |
| ECSP055576A (es) | Uso de derivados de ciclotiocarbamato en el tratamiento de las condiciones relacionadas con hormonas | |
| AR011480A1 (es) | ACIL-ANILIDAS SUSTITUIDAS CON RADICALES (HETERO) CICLICOS, NO ESTEROIDALES, CON ACTIVIDAD GESTÁGENA Y ANDRoGENA MIXTA. | |
| ES2337129T3 (es) | Sistema de administracion de medicamento comprendiendo un estrogeno tetrahidroxilado para el uso en la anticoncepcion hormonal. | |
| ECSP055574A (es) | Uso de derivados de tio-oxindol en el tratamiento de condiciones relacionadas con hormonas. | |
| DK0792152T3 (da) | Fremgangsmåder til svangerskabsforebyggelse | |
| AR025457A1 (es) | Mesoprogestinas (moduladores de receptores de progesterona) para el tratamiento y la prevencion de trastornos ginecologicos benignos hormona-dependientes | |
| UA37259C2 (uk) | Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч | |
| MXPA05005897A (es) | Derivados tetraciclicos novedosos, que contienen heteroatomos, como moduladores selectivos del receptor de estrogeno. | |
| JP2010539153A5 (es) | ||
| ECSP055530A (es) | Estratrienos 9-alfa-sustituidos como estrógenos de eficacia selectiva | |
| Mosbah | A modified one-stage repair of third-degree rectovestibular lacerations in mares | |
| CO5190694A1 (es) | Mesoprogestinas (moduladores de receptores de progesterona) como componentes de anticonceptivos femeninos | |
| Murray | Natural progesterone: what role in women’s health care | |
| CO5200773A1 (es) | Mesoprogestinas (moduladores de receptores para progestero- na) como componente de composiciones utilizadas para la terapia de sustitucion hormonal (trh) | |
| UY26665A1 (es) | Estratrienos sustituidos como estrógenos selectivamente activos | |
| CZ205095A3 (en) | Inhibition process of ripening and/or fertilization of oocytes and a set for making thereof | |
| Fang et al. | Optimal routes of administration, vehicles and timing of progesterone treatment for inhibition of delivery during pregnancy | |
| WO2003041719A1 (en) | Method of contraception in mammalian females and pharmaceutical kit for use in such method | |
| Garcia et al. | Characteristics of ejaculated rat semen after lesion of scrotal nerves | |
| Prilepskaya et al. | Emergency hormonal contraception (literature review) | |
| PE20030411A1 (es) | DERIVADOS 8ß-SUSTITUIDOS DE 11ß-FENIL Y 11ß-HEXIL-ESTRA-1,3,5(10)-TRIENO QUE TIENEN AFINIDAD POR RECEPTORES DE ESTROGENO | |
| TAUSK | THE PHAR MALOLOGICAL INHIBITION OF THE OVARIAN FUNCTION | |
| NIEMAN | B3 THE USE OF ANTIPROGESTINS IN THE REPRODUCTIVE CYCLE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |